-
Mashup Score: 8Sodium–glucose co-transporter inhibitors—who would have guessed? - 13 day(s) ago
“Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have spoken on this matter, this is definitely true and a demanding reality in medical research.1 For the pharmaceutical industry, predicting the effectiveness of drugs is a major concern, and finding a blockbuster drug is challenging but highly warranted. Few people had predicted the broad effects of the sodium–glucose co-transporter (SGLT) inhibitor class when initially developing a diabetes drug that increased glucose excretion in urine.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet
-
Mashup Score: 2More options for young children with type 1 diabetes - 13 day(s) ago
Hybrid closed-loop insulin delivery systems are transforming the management of type 1 diabetes. Young children with type 1 diabetes are arguably the most challenging age group to manage, due to inconsistent food intake, unpredictable activity, and inability to reliably communicate symptoms of hypoglycaemia. The management burden on carers is substantial, with many parents of young children with type 1 diabetes not able to work due to their caregiver commitments. Among all age groups, young children also have the highest variability in day-to-day insulin requirements, highlighting the importance of automated insulin delivery systems in this population.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Charlotte K Boughton comments on: More options for young children with type 1 #diabetes https://t.co/FnY2xWtX0B #T1D
-
-
Mashup Score: 35Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial - 13 day(s) ago
Sotagliflozin reduced MACE, with independent reductions in myocardial infarction and stroke, among patients with type 2 diabetes, chronic kidney disease, and additional cardiovascular risk. The ischaemic benefit on both myocardial infarction and stroke has not been previously observed with other SGLT inhibitors and warrants investigation of combined SGLT1 and SGLT2 inhibition as a possible underlying mechanism.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
Online—Effect of #sotagliflozin on major adverse #cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial https://t.co/CZ5KleShIl #SGLT1/2 inhibitor #T2D #CKD #CVD https://t.co/tdcbRuiRqd
-
-
Mashup Score: 23Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial - 13 day(s) ago
In children aged 2–6 years with type 1 diabetes, the TIR with the MiniMed 780G system in auto mode was non-inferior to that in manual+SBL mode. The significantly improved TIR and HbA1c in favour of auto mode could help prevent diabetes-related complications. Additionally, the observed safety profile in auto mode was acceptable.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial https://t.co/jNM4tCUy5T #T1D
-
-
Mashup Score: 1Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes | American Diabetes Association - 13 day(s) ago
Today, a new study demonstrates inhaled insulin as a safe and effective replacement for rapid-acting meal insulin in children with type 1 diabetes.
Source: diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
PRESS RELEASE: Inhaled Insulin Shown as a Safe and Effective Replacement for Standard-of-Care in Children with Type 1 Diabetes Details: https://t.co/lUpvwa8DW8 #ADASciSessions https://t.co/OTY9Q5XCcJ
-
-
Mashup Score: 3Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy | American Diabetes Association - 13 day(s) ago
Today, findings from the QWINT-1 study found once-weekly insulin efsitora alfa (efsitora) lowered blood glucose (blood sugar) levels as effectively as daily basal insulin in insulin-naïve type 2 diabetes.
Source: diabetes.orgCategories: General Medicine News, EndocrinologyTweet-
PRESS RELEASE: Once-Weekly Insulin Efsitora Achieves Comparable A1C Reduction to Daily Insulin Therapy Details: https://t.co/GGK58BL5SE #ADASciSessions https://t.co/zzIW0R9YNP
-
-
Mashup Score: 0
CHICAGO — Adults with overweight or obesity who received once-weekly ecnoglutide, a novel GLP-1 receptor agonist, had superior and sustained reductions in body weight compared with placebo, according to data from the phase 3 SLIMMER study.Ecnoglutide (Sciwind Biosciences) had a favorable safety profile and improved other key cardiometabolic risk factors, while also reducing liver fat
Source: www.healio.comCategories: General Medicine News, EndocrinologyTweet-
💉A once-weekly novel #GLP1 conferred weight loss of up to 13.2% with a 2.4 mg dose for adults with overweight or #obesity. Learn more about ecnoglutide here: https://t.co/rGyqeNVZwT #ADA2025 @ADA_DiabetesPro #ADASciSessions
-
-
Mashup Score: 90
In 2023, consensus was reached that a diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD)1 could be assigned if a person showed evidence of hepatic steatosis with no aetiological factors other than the presence of one metabolic syndrome trait (as defined by Alberti and colleagues2). Although non-alcoholic fatty liver disease (as the condition was previously referred to) has been considered a multisystem disease3 for the past decade, the new nomenclature and diagnostic criteria focus attention on metabolic dysfunction, which is a welcome step forward.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—Type 2 #diabetes, #prediabetes, and #MASLD: who and when to screen and how to treat? https://t.co/YLG4mAX458 #T2D
-
-
Mashup Score: 46GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study - 13 day(s) ago
GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.
Source: www.thelancet.comCategories: General Medicine News, EndocrinologyTweet-
New—GLP-1 receptor agonists in #kidney #transplant recipients with pre-existing #diabetes: a retrospective cohort study https://t.co/kIwzXjVE1Z #GLP-1 receptor agonists #T2D https://t.co/CdrxDSJKAM
-
-
Mashup Score: 3Membership - 13 day(s) ago
Learn more about becoming a member of the Endocrine Society and ensure your connection with an international body of more than 18,000 motivated researchers and practitioners from over 120 countries.
Source: www.endocrine.orgCategories: General Medicine News, EndocrinologyTweet-
Carve some time out to renew your membership! Keep your benefits alive, such as discounts to our annual meeting, ENDO, access to member-exclusive networking opportunities, and publishing discounts. They’re worth howling about: https://t.co/VbJqGfi9oZ https://t.co/3pl9Nj8BZA
-
Anna Norhammar & Viveca Ritsinger comment on: Sodium–glucose co-transporter inhibitors—who would have guessed? https://t.co/poTWbTPLnh #SGLT1/2 inhibitor #T2D #CKD #CVD